Genfleet
2 known investors
Genfleet Therapeutics (HK: 2595) is a drug development company focused on oncology and immunological diseases, building large- and small-molecule pipelines targeting novel, clinically unvalidated targets and indications. Its approved product Dabote (fulzerasib) is a KRAS G12C inhibitor, and the company develops a matrix of RAS-targeted therapies along with dual-target treatments.
Investors · 2
Frequently asked questions
- What does Genfleet do?
- Genfleet Therapeutics (HK: 2595) is a drug development company focused on oncology and immunological diseases, building large- and small-molecule pipelines targeting novel, clinically unvalidated targets and indications. Its approved product Dabote (fulzerasib) is a KRAS G12C inhibitor, and the company develops a matrix of RAS-targeted therapies along with dual-target treatments.
- Who are Genfleet's investors?
- Genfleet's investors include HM Venture Partners, Pan-Lin Capital.